

Claims

1. Use of an antibody that comprises a variable domain that comprises a heavy chain variable region comprising a CDR1 having SEQ ID NO: 24, a CDR2
5 having SEQ ID NO: 26, and a CDR3 having SEQ ID NO: 28; and a variable domain that comprises a heavy chain variable region comprising a CDR1 having SEQ ID NO: 87, a CDR2 having SEQ ID NO: 89, and a CDR3 having SEQ ID NO: 91, wherein both variable domains comprise a light chain variable region comprising a CDR1 comprising SEQ ID NO: 127, a CDR2 comprising
10 SEQ ID NO: 128 and a CDR3 comprising SEQ ID NO: 129 for the manufacture of a medicament for the treatment of cancer in a subject wherein the cancer expresses LGR5 and/or expresses EGFR, and with a flat dose of 1500 mg of the antibody.
- 15 2. The use according to claim 1, wherein the cancer is gastric, esophageal, or gastro-esophageal-junction cancer.
3. The use according to claim 1 or 2, wherein the cancer expresses EGFR and LGR5.
20
4. The use according to any one of the preceding claims, wherein the medicament is formulated for intravenous administration.
5. The use according to any one of the preceding claims, wherein the
25 medicament is to be administered weekly, biweekly or monthly.
6. The use according to any one of the preceding claims, wherein the medicament is to be administered once every 2 weeks.
- 30 7. The use according to claim 1, wherein the cancer is esophageal cancer.

8. The use according to claim 7, wherein the esophageal cancer is esophageal squamous cell carcinoma (ESCC).

5 9. The use according to claim 1, wherein the cancer is gastric cancer.

10. The use according to any one of the preceding claims, wherein a VH chain of the variable domain that binds EGFR comprises the amino acid sequence of VH chain MF3755 as depicted in SEQ ID NO: 4; and wherein a VH chain of
10 the variable domain that binds LGR5 comprises the amino acid sequence of VH chain MF5816 as depicted in SEQ ID NO: 13 and wherein both variable domains comprise the light chain variable region having SEQ ID NO: 122.

11. The use according to any one of the preceding claims, wherein the antibody
15 is afucosylated.

12. The use according to any one of the preceding claims, where the antibody is a human IgG antibody.

20 13. The use according to any one of the preceding claims, where the antibody is a human IgG1 antibody.

14. The use according to any one of the preceding claims, wherein the antibody is a bispecific antibody.

25